Perioperative treatment for muscle invasive bladder cancer in the era of immunotherapy. (PubMed, Ther Adv Urol) - Aug 30, 2026 - "The phase III trials, KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304 have established perioperative enfortumab vedotin plus pembrolizumab as a new standard of care for neoadjuvant therapy. This review synthesizes the evolving role of perioperative therapies in MIBC, from the historical reliance on cisplatin-based chemotherapy to the transformative integration of immunotherapy, ADCs, and biomarker-guided approaches. Together, these advances represent a significant progress in perioperative bladder cancer care, heralding a shift toward individualized, biomarker-driven strategies that promise improved survival and broader treatment applicability."
IO biomarker • Journal • Review • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
|
|
Cheyenne Williams; Leilei Xia; Yash Shah
|